|
|
 |
|
Viewing report
|
|
|
|
Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases
Decision Resources, Inc, June 2011
Despite ongoing research in drug safety and efficacy, even physicians agree that the ability to predict response to high-priced autoimmune biologics is a largely untapped field. Biomarkers are the ideal vehicles to elucidate information about patients who will respond satisfactorily to targeted therapies and to stratify patients according to disease severity so the most appropriate treatment can be delivered to the right patients. Will pharmaceutical and biotechnology companies invest in biomarkers and biomarker-based companion tests to further enhance the revolutionary value of biologics?
Also includes analysis from a survey of 78 physicians (27 gastroenterologists, 26 rheumatologists, and 25 dermatologists) fielded by Decision Resources in April 2011
Questions Answered:
- Although current biological autoimmune therapies are efficacious, they are not successful in all patients and can inflict harmful toxicities. How often are biological agents used as first-line therapies? How can biomarkers help shed light on how specific patients will respond to biological agents? In what autoimmune indication do we see the most promise for biomarker-enabled prescribing?
- Understanding biological pathways and discovering biomarkers are keys to future success in the autoimmune disease markets. What are the barriers and opportunities in this arena for more-robust prescribing of biologics? What do rheumatologists, dermatologists, and gastroenterologists say about the use of biomarkers and diagnostics for autoimmune/inflammatory diseases?
- An analysis of dealmaking activity shows that large- and small-capital-backed companies appear to have similar strategic goals when it comes to use of biomarkers in autoimmune biologics development. What other strategic trends are revealed for other company types after an analysis of 46 transactions performed across 71 entities over 65 months?
Scope:
Indications covered: rheumatology (rheumatoid arthritis, ankylosing spondylitis, osteoarthritis), gastroenterology (Crohn’s disease and ulcerative colitis), and dermatology (psoriasis and systemic lupus erythematosus).
Primary research: insight from physician survey of 78 specialists (27 gastroenterologists, 26 rheumatologists, and 25 dermatologists) that was fielded by Decision Resources in April 2011; includes data from ongoing clinical trials as reported in clinicaltrials.gov; additional research analysis from ChartTrends: Rheumatoid Arthritis 2010, a report by BioTrends Research Group, a Decision Resources, Inc., company.
Dealmaking assessment: analysis of 46 deals featuring 71 unique companies/entities between 2005 and May 2011.
Exhibits: 18 data-rich tables and figures
|
|
|
|
